Novartis Pharmaceuticals Gmbh Reports Findings in Psoriatic Arthritis (Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: a Health Insurance Claims Database Analysis)

2021 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Autoimmune Diseases and Conditions - Psoriatic Arthritis is the subject of a report. According to news reporting out of Basel, Switzerland, by NewsRx editors, research stated, “Psoriatic arthritis is a frequent manifestation of psoriasis, and has a high level of impact on physical functioning, work ability and quality of life. However, there have been few studies of the epidemiology, development of, and risk factors for concomitant psoriatic arthritis in patients with psoriasis.”

Our news journalists obtained a quote from the research from Novartis Pharmaceuticals Gmbh, “This study analysed data from a German public health insurance database of >2 million individuals. Factors influencing the development of psoriatic arthritis were determined by descriptively analysing comorbidities and Cox regression modelling. The prevalences of psoriasis and psoriatic arthritis were 2.63% and 0.29% in adults (18+ years) and, respectively, 0.30% and 0.01% in children (0-17 years). The proportion of adult patients with incident psoriasis who developed concomitant psoriatic arthritis within 5 years after diagnosis of psoriasis (mean 2.3 years) was 2.6%. Cardiovascular diseases are the most frequent comorbidity in patients with psoriasis with or without concomitant psoriatic arthritis.”

According to the news editors, the research concluded: “Depression and neurosis/stress disorder were identified as indicators for the development of psoriatic arthritis.”

For more information on this research see: Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: a Health Insurance Claims Database Analysis. Acta Dermato Venereologica, 2021:0. Acta Dermato Venereologica can be contacted at: Acta Dermato-venereologica, Tradgardsgatan 14, Uppsala, Se-753 09, Sweden.

Our news journalists report that additional information may be obtained by contacting Maximilian Reinhardt, Novartis Pharmaceuticals Gmbh, Basel, Switzerland. Additional authors for this research include Claudia Garbe, Jana Petersen, Matthias Augustin, Nathalia Kirsten, Mona H. C. Biermann, Benjamin Haberle and Kristina Hagenstrom.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.2340/00015555-3879. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Acta Dermato Venereologica is: Acta Dermato-venereologica, Tradgardsgatan 14, Uppsala, Se-753 09, Sweden.

(Our reports deliver fact-based news of research and discoveries from around the world.)